156
Participants
Start Date
March 28, 2017
Primary Completion Date
May 16, 2019
Study Completion Date
May 16, 2019
SHP640
Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
Placebo
Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
Fichte, Endl and Elmer Eyecare, Niagara Falls
Piedmont Eye Center, Inc., Lynchburg
Bowden Eye & Associates, Jacksonville
South Florida Research Center Inc., Miami
Bruce A. Segal, MD, PA, Delray Beach
International Research Center, Tampa
Shettle Eye Research, Inc., Largo
Sabates Eye Centers, Leawood
Physicians to Children & Adolescents, Bardstown
The Eye Care Institute, Louisville
The Ohio State University, Columbus
Cleveland Eye Clinic, Cleveland
Apex Eye Kenwood, Cincinnati
Washington University, St Louis
Tekwani Vision Center, St Louis
Silverstein Eye Centers, Kansas City
IPS Research Company, Oklahoma City
Houston Eye Associates, Houston
Sun Research Institute, LLC, San Antonio
Eyeland Vision, El Paso
Saltzer Medical Group, Nampa
Jean Brown Research, Salt Lake City
Chrysalis Clinical Research, St. George
Wellish Vision Institute, Las Vegas
University of Southern California, Los Angeles
Wolstan and Goldberg Eye Associates, Torrance
Lugene Eye Institute Inc, Glendale
Danbury Eye Physicians and Surgeons, Danbury
Shire Call Center, Lexington
Emanuelli Research & Development Center, LLC, Arecibo
University Of Puerto Rico, School of Medicine, Carolina
Lead Sponsor
Shire
INDUSTRY